Department of Pharmacy, Ricardo Bermingham Hospital-Matia Foundation, 20018 Donostia, Spain.
Department of Physiology, University of the Basque Country (UPV/EHU), 48940 Bilbao, Spain.
Int J Environ Res Public Health. 2023 Feb 17;20(4):3542. doi: 10.3390/ijerph20043542.
This study aimed to comparatively analyze the effect of the person-centered prescription (PCP) model on pharmacotherapeutic indicators and the costs of pharmacological treatment between a dementia-like trajectory and an end-stage organ failure trajectory, and two states of frailty (cut-off point 0.5). A randomized controlled trial was conducted with patients aged ≥65 years admitted to a subacute hospital and identified by the Necessity of Palliative Care test to require palliative care. Data were collected from February 2018 to February 2020. Variables assessed included sociodemographic, clinical, degree-of-frailty, and several pharmacotherapeutic indicators and the 28-day medication cost. Fifty-five patients with dementia-like trajectory and 26 with organ failure trajectory were recruited observing significant differences at hospital admission in the mean number of medications (7.6 vs. 9.7; < 0.004), the proportion of people on more than 10 medications (20.0% vs. 53.8%; < 0.002), the number of drug-drug interactions (2.7 vs. 5.1; < 0.006), and the Medication Regimen Complexity Index (MRCI) (25.7 vs. 33.4; < 0.006), respectively. Also, regarding dementia-like patients, after application of the PCP model, these patients improved significantly in the intervention group compared to the control group in the mean number of chronic medications, STOPP Frail Criteria, MRCI and the 28-day cost of regular medications ( < 0.05) between admission and discharge. As for the PCP effect on the control and the intervention group at the end-stage organ failure, we did not observe statistically significant differences. On the other hand, when the effect of the PCP model on different degrees of frailty was evaluated, no unequal behavior was observed.
本研究旨在比较分析以患者为中心的处方(PCP)模式对痴呆样轨迹和终末期器官衰竭轨迹以及两种虚弱状态(截断值 0.5)的药物治疗指标和药物治疗费用的影响。这是一项随机对照试验,纳入了年龄≥65 岁、因需要姑息治疗而被姑息治疗需求测试识别为需要姑息治疗的亚急性医院患者。数据收集时间为 2018 年 2 月至 2020 年 2 月。评估的变量包括社会人口统计学、临床、虚弱程度以及多项药物治疗指标和 28 天药物费用。共纳入 55 例痴呆样轨迹患者和 26 例器官衰竭轨迹患者,在入院时观察到药物数量(7.6 对 9.7; < 0.004)、服用超过 10 种药物的比例(20.0%对 53.8%; < 0.002)、药物相互作用数量(2.7 对 5.1; < 0.006)和药物管理方案复杂指数(MRCI)(25.7 对 33.4; < 0.006)存在显著差异。此外,对于痴呆样患者,在应用 PCP 模型后,干预组与对照组相比,慢性药物数量、STOPP 虚弱标准、MRCI 和常规药物 28 天费用在入院和出院时均显著改善( < 0.05)。至于 PCP 对终末期器官衰竭患者的控制和干预组的影响,我们没有观察到统计学上的显著差异。另一方面,当评估 PCP 模型对不同程度虚弱的影响时,没有观察到不平等的行为。